We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.62 | 1.25% | 50.19 | 50.18 | 50.20 | 50.36 | 49.9508 | 50.23 | 870,249 | 17:21:45 |
From Nov 2023 to May 2024
By Dean Seal
Teva Pharmaceuticals has closed a collaboration deal to co-develop and co-commercialize an inflammatory bowel disease treatment with Sanofi.
The deal, first disclosed on Oct. 4, calls for Teva to receive a $500 million upfront payment after closing and up to $1 billion in development and launch milestones for TEV '574, a treatment of ulcerative colitis and Crohn's disease that's in Phase 2b clinical trials.
The companies will equally share the global development costs and net profits and losses in major markets. Other markets are subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 program.
Teva is charged with leading commercialization of the product in Europe, Israel and specified other countries, while Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world.
Initial program results are expected to be available in 2024.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
November 30, 2023 09:08 ET (14:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
